These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31982258)

  • 41. Oral cholera vaccination coverage in an acute emergency setting in Somalia, 2017.
    Lubogo M; Mohamed AM; Ali AH; Ali AH; Popal GR; Kiongo D; Bile KM; Malik M; Abubakar A
    Vaccine; 2020 Feb; 38 Suppl 1():A141-A147. PubMed ID: 31980193
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A reactive vaccination campaign with single dose oral cholera vaccine (OCV) during a cholera outbreak in Cameroon.
    Amani A; Tatang CA; Bayiha CN; Woung M; Ngo Bama S; Nangmo A; Mbang MA; Epee Douba E
    Vaccine; 2021 Feb; 39(8):1290-1296. PubMed ID: 33494966
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India.
    Raghava Mohan V; Raj S; Dhingra MS; Aloysia D'Cor N; Singh AP; Saluja T; Kim DR; Midde VJ; Kim Y; Vemula S; Narla SK; Sah B; Ali M
    PLoS One; 2019; 14(6):e0218033. PubMed ID: 31211792
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Quantitative Systematic Review and Meta-Analysis of the Effectiveness of Oral Cholera Vaccine as a Reactive Measure in Cholera Outbreaks.
    Schwerdtle P; Onekon CK; Recoche K
    Prehosp Disaster Med; 2018 Feb; 33(1):2-6. PubMed ID: 29317005
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Unmasking herd protection by an oral cholera vaccine in a cluster-randomized trial.
    Ali M; Qadri F; Kim DR; Islam T; Im J; Ahmmed F; Chon Y; Islam Khan A; Zaman K; Marks F; Clemens JD
    Int J Epidemiol; 2019 Aug; 48(4):1252-1261. PubMed ID: 30968110
    [TBL] [Abstract][Full Text] [Related]  

  • 46. When, how, and where can oral cholera vaccines be used to interrupt cholera outbreaks?
    Clemens J; Holmgren J
    Curr Top Microbiol Immunol; 2014; 379():231-58. PubMed ID: 24402712
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety of a bivalent, killed, whole-cell oral cholera vaccine in pregnant women in Bangladesh: evidence from a randomized placebo-controlled trial.
    Khan AI; Ali M; Lynch J; Kabir A; Excler JL; Khan MA; Islam MT; Akter A; Chowdhury F; Saha A; Khan IA; Desai SN; Kim DR; Saha NC; Singh AP; Clemens JD; Qadri F
    BMC Infect Dis; 2019 May; 19(1):422. PubMed ID: 31092224
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The case for ring vaccinations with special consideration of oral cholera vaccines.
    Deen J; von Seidlein L
    Hum Vaccin Immunother; 2018; 14(8):2069-2074. PubMed ID: 29630444
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Innovative vaccine delivery strategies in response to a cholera outbreak in the challenging context of Lake Chilwa. A rapid qualitative assessment.
    Heyerdahl LW; Ngwira B; Demolis R; Nyirenda G; Mwesawina M; Rafael F; Cavailler P; Bernard Le Gargasson J; Mengel MA; Gessner BD; Guillermet E
    Vaccine; 2018 Oct; 36(44):6491-6496. PubMed ID: 29126808
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Validity of the estimates of oral cholera vaccine effectiveness derived from the test-negative design.
    Ali M; You YA; Sur D; Kanungo S; Kim DR; Deen J; Lopez AL; Wierzba TF; Bhattacharya SK; Clemens JD
    Vaccine; 2016 Jan; 34(4):479-485. PubMed ID: 26707378
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Local perceptions of cholera and anticipated vaccine acceptance in Katanga province, Democratic Republic of Congo.
    Merten S; Schaetti C; Manianga C; Lapika B; Chaignat CL; Hutubessy R; Weiss MG
    BMC Public Health; 2013 Jan; 13():60. PubMed ID: 23339647
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The cholera outbreak in Yemen: lessons learned and way forward.
    Federspiel F; Ali M
    BMC Public Health; 2018 Dec; 18(1):1338. PubMed ID: 30514336
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The potential impact of case-area targeted interventions in response to cholera outbreaks: A modeling study.
    Finger F; Bertuzzo E; Luquero FJ; Naibei N; Touré B; Allan M; Porten K; Lessler J; Rinaldo A; Azman AS
    PLoS Med; 2018 Feb; 15(2):e1002509. PubMed ID: 29485987
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of Oral Cholera Vaccine and Knowledge, Attitudes, and Practices Regarding Safe Water, Sanitation and Hygiene in a Long-Standing Refugee Camp, Thailand, 2012-2014.
    Scobie HM; Phares CR; Wannemuehler KA; Nyangoma E; Taylor EM; Fulton A; Wongjindanon N; Aung NR; Travers P; Date K
    PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005210. PubMed ID: 27992609
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High cholera vaccination coverage following emergency campaign in Haiti: Results from a cluster survey in three rural Communes in the South Department, 2017.
    Sharp A; Blake A; Backx J; Panunzi I; Barrais R; Nackers F; Luquero F; Deslouches YG; Cohuet S
    PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007967. PubMed ID: 32004316
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oral Cholera Vaccine Coverage during an Outbreak and Humanitarian Crisis, Iraq, 2015.
    Lam E; Al-Tamimi W; Russell SP; Butt MO; Blanton C; Musani AS; Date K
    Emerg Infect Dis; 2017 Jan; 23(1):38-45. PubMed ID: 27983502
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The interplay between WASH practices and vaccination with oral cholera vaccines in protecting against cholera in urban Bangladesh: Reanalysis of a cluster-randomized trial.
    Chowdhury F; Aziz AB; Ahmmed F; Ahmed T; Kang SS; Im J; Park J; Tadesse BT; Islam MT; Kim DR; Hoque M; Pak G; Khanam F; McMillan NAJ; Liu X; Zaman K; Khan AI; Kim JH; Marks F; Qadri F; Clemens JD
    Vaccine; 2023 Mar; 41(14):2368-2375. PubMed ID: 36898931
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The projected impact of geographic targeting of oral cholera vaccination in sub-Saharan Africa: A modeling study.
    Lee EC; Azman AS; Kaminsky J; Moore SM; McKay HS; Lessler J
    PLoS Med; 2019 Dec; 16(12):e1003003. PubMed ID: 31825965
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Randomized, Placebo-Controlled Trial Evaluating Safety and Immunogenicity of the Killed, Bivalent, Whole-Cell Oral Cholera Vaccine in Ethiopia.
    Desai SN; Akalu Z; Teshome S; Teferi M; Yamuah L; Kim DR; Yang JS; Hussein J; Park JY; Jang MS; Mesganaw C; Taye H; Beyene D; Bedru A; Singh AP; Wierzba TF; Aseffa A
    Am J Trop Med Hyg; 2015 Sep; 93(3):527-533. PubMed ID: 26078323
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Herd protection by a bivalent killed whole-cell oral cholera vaccine in the slums of Kolkata, India.
    Ali M; Sur D; You YA; Kanungo S; Sah B; Manna B; Puri M; Wierzba TF; Donner A; Nair GB; Bhattacharya SK; Dhingra MS; Deen JL; Lopez AL; Clemens J
    Clin Infect Dis; 2013 Apr; 56(8):1123-31. PubMed ID: 23362293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.